Biographies | Haoma Medica

BIOGRAPHIES

Dr. Cenk Oguz, Founder & Chief Medical Officer

Dr. Cenk Oguz is the Founder and Chief Medical Officer of Haoma Medica, with a particular focus on its nutraceutical subsidiary, Naquinate. As a member of both the Management and Scientific Committees, he plays a leading role in shaping the company’s clinical vision, scientific direction, and long-term strategy in preventive bone health.

Alongside his work in industry, Dr Oguz serves as a Consultant Trauma and Orthopaedic Surgeon at North-West University Healthcare NHS Trust in London. In this role, he leads teams of senior and junior doctors and oversees the care of both trauma and elective patients across inpatient, outpatient, surgical, and emergency settings.

His day-to-day clinical practice gives him a direct and practical understanding of musculoskeletal health across the full continuum of care, from acute intervention through to recovery and long-term prevention.

Dr Oguz has been instrumental in the development of Naquinate, a clinically anchored intervention designed for patients in the Osteopenic Window, the under-recognised diagnostic space between normal bone density and osteoporosis. He led the scientists and researchers behind the in vitro and in vivo studies that generated the evidence base supporting a successful MHRA application for Phase I human clinical trials.

He also worked closely with the internationally respected clinical research organisation Parexel, helping ensure that the trials were conducted with full compliance, scientific rigour, and operational precision. His work is grounded in a clear ambition: to position Naquinate as the world’s first biomarker-validated bone preservation supplement. Framed not as a drug, not as a vitamin, and not as a generic wellness product, Naquinate has been developed as a physician-guided, evidence-supported, and clinically measurable intervention for the prevention of osteoporosis.

Under Dr Oguz’s leadership, the strategy has centred on measurable biomarker response, protocol-driven care, and early intervention, helping define a new category in pre-osteoporotic care before the wider market has named it.

In addition to his clinical and scientific leadership, Dr Oguz brings substantial entrepreneurial and strategic experience. He has held co-founder, director, and board-level roles in ventures focused on osteoporosis treatment, supported globally patented innovation, and contributed to successful fundraising across early-stage growth rounds.

His broader clinical and scientific interests within health span medicine include stem cell science, peptide-based therapeutics, and the preservation of musculoskeletal function, reflecting a career dedicated to advancing clinically meaningful strategies in prevention, regenerative medicine, and orthopaedic health.

What makes Dr Oguz particularly distinctive is the breadth of expertise he brings across molecular medicine, cellular biology, and frontline orthopaedic care, combining deep scientific literacy at the level of mechanism and pathway with the practical authority that comes from years of consultant-level experience treating patients in trauma and orthopaedic settings.

His academic background, advanced surgical training, and extensive clinical practice allow him to understand bone health from the inside out, from cellular function and biological signalling through to diagnosis, treatment decisions, patient outcomes, and the realities of care delivery in modern healthcare systems.

That combination is exceptionally rare. It gives him a unique ability to translate science into practice, connect innovation with clinical need, and lead the development of interventions that are not only biologically credible but medically relevant and commercially meaningful.

Dr Oguz holds an FRCS in Trauma and Orthopaedics, an MSc in Surgical Sciences from the University of London, an MBBS from the Royal Free Hospital School of Medicine, and a BSc in Molecular Medicine. He is also a member of the British Orthopaedic Association, the American Academy of Orthopaedic Surgeons, and the General Medical Council in the UK.

The team from Haoma Medica has published more than 75 peer-reviewed research papers across a variety of bone-related topics, including:

‘A Natural Naphthoquinone (Naquinate; NQ8) Causes Increased Release of Osteoprotegerin and Osteocalcin by Cultured Primary Human Femoral Osteoblasts Through a Wnt16-mediated Mechanism of Action for Periosteal Expansion and Reduced Cortical Porosity in a Bilateral OVx Rat Model of Rapid Bone Loss’

Publication and Poster Presentation, Orthopaedic Research Society (ORS), Phoenix, Arizona, USA 2025. Presented by Dr Cenk Oguz.

Proffesor Stephen Hodges, Founder & Chairman

Professor Stephen Hodges, Founder and Executive Chairman, member of the Management and Scientific Committees and member of the Board of Haoma Medica. Stephen has been a Senior Lecturer at University College London and Sheffield University and an Honorary Fellow of The Royal Veterinary College, London.

He held a Professorial position at Tromsø University Hospital in the Institute of Clinical Medicine and is a senior scientific advisor for the development of novel large-animal models of acute and critical human diseases.

Stephen discovered NaQuinate/Osteopura and has expertise gained across several academic environments, working with leading clinical and scientific experts in skeletal, liver, and renal health. In addition to his academic activities, Stephen has considerable experience gained through work with pharmaceutical and biotech companies and University-based drug and intellectual property development companies.

Stephen’s academic background has spanned several aligned but separate subjects. Originally starting his career as an organic chemist before studying at a postgraduate level in protein biochemistry, which led directly to a PhD in physiology and pharmacology of neurotoxic peptide snake venom toxins.

Subsequent appointments moved Stephen into cell biology and highly focused analytical techniques using both chemical, chromatographic, and antibody technologies. Stephen has held an advanced animal surgery licence and has developed rodent and large-animal models to investigate major human skeletal, liver, and kidney diseases.

Working with leading clinical investigators, Stephen has been intimately involved in human Phase I and II clinical trials.

The multifaceted background Stephen has built over 30+ years of experience, culminating in the development of Naquinate as a preventative measure to reduce fracture incidence, ideally places him to oversee the clinical phase of human development of Naquinate.

Stephen has published over 70 peer reviewed papers and book chapters and continues to publish on the developments at Haoma Medica including the genetic understanding of reduced fracture rate in African American women with respect to Caucasian women with Professor Arnett (UCL, Emeritus).

Outside of Haoma Medica, Stephen is a principle Visiting Professor in the Department of Anaesthesia and Intensive Care Medicine at the Arctic University Hospital of North Norway in Tromsø, studying large animal models of critical metabolic renal disease with Professor Lars Marius Ytrebø and Professor Ole Martin Fuskevåg.